Two investigational Alzheimer’s immunotherapies failed to show any benefit in a series of phase III trials comprising more than 4,000 patients.

Neither bapineuzumab, which targets soluble and...

Field of Interest: Geriatrics

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.